Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
25/03 | North American Morning Briefing : Tech in Focus on -2- | DJ |
2023 | Bidding Procedure Approved for 9 Meters Biopharma, Inc. | CI |
Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Profitability | |||||||
Return on Assets | -311.44 | -258.31 | -58.07 | -43.74 | -63.03 | ||
Return on Total Capital | 1.09K | 625.98 | -99.35 | -52.7 | -82.19 | ||
Return On Equity % | 305.2 | 407.57 | -545.95 | -99.75 | -198.92 | ||
Return on Common Equity | 305.2 | 407.57 | -545.95 | -99.75 | -198.92 | ||
Short Term Liquidity | |||||||
Current Ratio | 0.63 | 0.35 | 5.68 | 5.91 | 1.08 | ||
Quick Ratio | 0.57 | 0.31 | 5.53 | 5.56 | 0.41 | ||
Operating Cash Flow to Current Liabilities | -1.5 | -1.21 | -2.83 | -3.49 | -1.21 | ||
Long Term Solvency | |||||||
Total Debt/Equity | -142.02 | -33.57 | 0.72 | 0.4 | 821.87 | ||
Total Debt / Total Capital | 337.97 | -50.54 | 0.71 | 0.4 | 89.15 | ||
LT Debt/Equity | - | - | 0.52 | 0.27 | 2.14 | ||
Long-Term Debt / Total Capital | - | - | 0.52 | 0.27 | 0.23 | ||
Total Liabilities / Total Assets | 156.69 | 281.51 | 17.92 | 17.08 | 92.76 | ||
EBIT / Interest Expense | -2.94 | -13.3 | -5.1 | -662.42 | -15.75 | ||
EBITDA / Interest Expense | -2.93 | -13.26 | -5.08 | -660.74 | -15.72 | ||
(EBITDA - Capex) / Interest Expense | -2.94 | -13.27 | -5.08 | -661.01 | -15.72 | ||
Total Debt / EBITDA | -0.29 | -0.13 | -0.01 | -0.01 | -0.47 | ||
Net Debt / EBITDA | 0.03 | 0.06 | 1.83 | 1.5 | -0.17 | ||
Total Debt / (EBITDA - Capex) | -0.29 | -0.13 | -0.01 | -0.01 | -0.47 | ||
Net Debt / (EBITDA - Capex) | 0.03 | 0.06 | 1.83 | 1.5 | -0.17 | ||
Growth Over Prior Year | |||||||
EBITDA, 1 Yr. Growth % | 61.69 | 33.27 | -13.88 | 51.45 | 34.42 | ||
EBITA, 1 Yr. Growth % | 61.78 | 33.25 | -13.88 | 51.35 | 34.42 | ||
EBIT, 1 Yr. Growth % | 61.78 | 33.25 | -13.88 | 51.35 | 34.42 | ||
Earnings From Cont. Operations, 1 Yr. Growth % | 108.19 | 11.95 | 127.35 | -40.19 | 19 | ||
Net Income, 1 Yr. Growth % | 108.19 | 11.95 | 127.35 | -40.19 | 19 | ||
Normalized Net Income, 1 Yr. Growth % | 106.86 | 7.6 | 10.62 | 10.01 | 39.87 | ||
Diluted EPS Before Extra, 1 Yr. Growth % | -0.05 | -16.83 | -28.27 | -74.01 | 11.65 | ||
Net Property, Plant and Equip., 1 Yr. Growth % | -13.79 | 94.48 | 231.06 | -19.14 | -32.84 | ||
Total Assets, 1 Yr. Growth % | 708.3 | -17.93 | 639.28 | 28.13 | -33.93 | ||
Tangible Book Value, 1 Yr. Growth % | -69.95 | 162.75 | -434.33 | 29.44 | -94.23 | ||
Common Equity, 1 Yr. Growth % | -69.95 | 162.75 | -434.33 | 29.44 | -94.23 | ||
Cash From Operations, 1 Yr. Growth % | 197.64 | 18.45 | 8.02 | 51.87 | 26.34 | ||
Capital Expenditures, 1 Yr. Growth % | -64 | -14.41 | -78.69 | 390.6 | -77.22 | ||
Levered Free Cash Flow, 1 Yr. Growth % | 797.52 | -2.78 | 194.76 | 28.38 | 85.45 | ||
Unlevered Free Cash Flow, 1 Yr. Growth % | 1.81K | -26.88 | 221.89 | 19.31 | 86.14 | ||
Compound Annual Growth Rate Over Two Years | |||||||
EBITDA, 2 Yr. CAGR % | 82.57 | 47.42 | 6.47 | 14.2 | 42.68 | ||
EBITA, 2 Yr. CAGR % | 82.65 | 47.45 | 6.46 | 14.16 | 42.63 | ||
EBIT, 2 Yr. CAGR % | 82.65 | 47.45 | 6.46 | 14.16 | 42.63 | ||
Earnings From Cont. Operations, 2 Yr. CAGR % | 107.35 | 52.66 | 59.54 | 16.61 | -15.64 | ||
Net Income, 2 Yr. CAGR % | 107.35 | 52.66 | 59.54 | 16.61 | -15.64 | ||
Normalized Net Income, 2 Yr. CAGR % | 106.69 | 49.67 | 8.47 | 10.32 | 24.05 | ||
Diluted EPS Before Extra, 2 Yr. CAGR % | 134.03 | -8.82 | -22.76 | -56.82 | -46.13 | ||
Net Property, Plant and Equip., 2 Yr. CAGR % | 112.57 | 29.49 | 153.74 | 63.62 | -26.31 | ||
Total Assets, 2 Yr. CAGR % | 276.36 | 157.56 | 146.32 | 207.77 | -7.99 | ||
Tangible Book Value, 2 Yr. CAGR % | -25.47 | -11.14 | 196.38 | 108.02 | -72.67 | ||
Common Equity, 2 Yr. CAGR % | -25.47 | -11.14 | 196.38 | 108.02 | -72.67 | ||
Cash From Operations, 2 Yr. CAGR % | 164.22 | 87.76 | 13.12 | 28.09 | 38.52 | ||
Capital Expenditures, 2 Yr. CAGR % | 27.53 | -44.49 | -57.29 | 2.25 | 5.72 | ||
Levered Free Cash Flow, 2 Yr. CAGR % | - | 197.96 | 66.35 | 94.53 | 54.3 | ||
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | 275.85 | 50.72 | 95.97 | 49.02 | ||
Compound Annual Growth Rate Over Three Years | |||||||
EBITDA, 3 Yr. CAGR % | - | 64.85 | 22.72 | 19.74 | 20.58 | ||
EBITA, 3 Yr. CAGR % | - | 64.89 | 22.74 | 19.7 | 20.55 | ||
EBIT, 3 Yr. CAGR % | - | 64.89 | 22.74 | 19.7 | 20.55 | ||
Earnings From Cont. Operations, 3 Yr. CAGR % | - | 68.84 | 74.34 | 15.03 | 17.4 | ||
Net Income, 3 Yr. CAGR % | - | 68.84 | 74.34 | 15.03 | 17.4 | ||
Normalized Net Income, 3 Yr. CAGR % | - | 66.63 | 34.8 | 8.98 | 19.4 | ||
Diluted EPS Before Extra, 3 Yr. CAGR % | - | 65.77 | -15.83 | -46.28 | -40.74 | ||
Net Property, Plant and Equip., 3 Yr. CAGR % | - | 106.36 | 77.06 | 73.32 | 21.6 | ||
Total Assets, 3 Yr. CAGR % | - | 126.53 | 266.03 | 98.1 | 84.28 | ||
Tangible Book Value, 3 Yr. CAGR % | - | 13.43 | 38.21 | 124.86 | -37.03 | ||
Common Equity, 3 Yr. CAGR % | - | 13.43 | 38.21 | 124.86 | -37.03 | ||
Cash From Operations, 3 Yr. CAGR % | - | 102.22 | 56.16 | 24.79 | 27.5 | ||
Capital Expenditures, 3 Yr. CAGR % | - | 11.66 | -59.66 | -3.64 | -38.02 | ||
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | 193.45 | 52.58 | 91.45 | ||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | 252.73 | 39.43 | 92.64 | ||
Compound Annual Growth Rate Over Five Years | |||||||
EBITDA, 5 Yr. CAGR % | - | - | - | 41.99 | 30.35 | ||
EBITA, 5 Yr. CAGR % | - | - | - | 41.99 | 30.34 | ||
EBIT, 5 Yr. CAGR % | - | - | - | 41.99 | 30.34 | ||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | - | 45.6 | 30.4 | ||
Net Income, 5 Yr. CAGR % | - | - | - | 45.6 | 30.4 | ||
Normalized Net Income, 5 Yr. CAGR % | - | - | - | 40.96 | 30.39 | ||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | - | -3.22 | -29.59 | ||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | - | 88.06 | 24.69 | ||
Total Assets, 5 Yr. CAGR % | - | - | - | 156.07 | 110.69 | ||
Tangible Book Value, 5 Yr. CAGR % | - | - | - | 44.57 | -27.73 | ||
Common Equity, 5 Yr. CAGR % | - | - | - | 44.57 | -27.73 | ||
Cash From Operations, 5 Yr. CAGR % | - | - | - | 68.46 | 48.85 | ||
Capital Expenditures, 5 Yr. CAGR % | - | - | - | 7.79 | -40.69 | ||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 126.91 | ||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | - | 149.9 |
- Stock Market
- Equities
- NMTRQ Stock
- Financials 9 Meters Biopharma, Inc.
- Financial Ratios
MarketScreener is also available in this country: United States.
Switch edition